A detailed history of Assetmark, Inc transactions in Veracyte, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 2,744 shares of VCYT stock, worth $98,619. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,744
Previous 20,973 86.92%
Holding current value
$98,619
Previous $454,000 79.52%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$21.0 - $35.25 $382,809 - $642,572
-18,229 Reduced 86.92%
2,744 $93,000
Q2 2024

Aug 13, 2024

BUY
$18.86 - $23.55 $117,705 - $146,975
6,241 Added 42.36%
20,973 $454,000
Q1 2024

May 06, 2024

BUY
$21.0 - $29.1 $55,608 - $77,056
2,648 Added 21.91%
14,732 $326,000
Q4 2023

Feb 09, 2024

BUY
$19.72 - $28.68 $69,236 - $100,695
3,511 Added 40.95%
12,084 $332,000
Q3 2023

Oct 27, 2023

BUY
$22.33 - $29.92 $27,666 - $37,070
1,239 Added 16.89%
8,573 $191,000
Q2 2023

Aug 11, 2023

BUY
$20.96 - $26.99 $26,598 - $34,250
1,269 Added 20.92%
7,334 $186,000
Q1 2023

May 05, 2023

BUY
$20.58 - $27.89 $14,385 - $19,495
699 Added 13.03%
6,065 $135,000
Q4 2022

Feb 10, 2023

BUY
$15.31 - $29.94 $23,745 - $46,436
1,551 Added 40.66%
5,366 $127,000
Q3 2022

Nov 01, 2022

BUY
$16.58 - $27.9 $20,211 - $34,010
1,219 Added 46.96%
3,815 $63,000
Q2 2022

Aug 03, 2022

BUY
$15.45 - $29.52 $19,034 - $36,368
1,232 Added 90.32%
2,596 $52,000
Q1 2022

May 13, 2022

BUY
$21.94 - $42.51 $7,744 - $15,006
353 Added 34.92%
1,364 $38,000
Q4 2021

Feb 14, 2022

BUY
$36.09 - $53.79 $1,660 - $2,474
46 Added 4.77%
1,011 $42,000
Q4 2020

Feb 10, 2021

SELL
$32.49 - $61.88 $15,757 - $30,011
-485 Reduced 33.45%
965 $47,000
Q1 2020

May 12, 2020

BUY
$16.13 - $30.17 $4,839 - $9,051
300 Added 26.09%
1,450 $35,000
Q4 2019

Feb 11, 2020

BUY
$20.78 - $29.99 $23,897 - $34,488
1,150 New
1,150 $32,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.57B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.